ESCAPE TRIAL - Evaluation of PSMA PET-CT in Active Surveillance for Prostate CancEr

February 6, 2024

ESCAPE Trial design is described in this 3-minute explainer video.  The ESCAPE trial is titled Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr and is a study for prostate cancer patients considering active surveillance to delay treatment. Traditionally, PSA tests, biopsies, and MRI scans monitor cancer. However, new tests like PSMA PET scans aim to enhance accuracy. The trial investigates whether adding PSMA PET scans improves the detection of aggressive prostate cancer during active surveillance. Participants undergo standard tests along with PSMA PET scans before biopsy. Joining the trial supports patient decision-making for active surveillance by providing more precise information on prostate cancer evaluated by PSMA PET imaging.  

Read the Full Video Transcript

Narrator: This video is an overview of a new study for men with prostate cancer who are interested in avoiding treatment with active surveillance.

The main treatments for prostate cancer are surgery and radiation. However, surgery and radiation have side effects. Active surveillance is an option for men with low or favorable intermediate risk prostate cancer. The key benefit of active surveillance is it gives men with prostate cancer a chance to either delay or avoid side effects of treatment. In the past, doctors have used tests like PSA blood tests, biopsies, and MRI scans to monitor cancer in patients In active surveillance.

However, there are newer tests that may increase the accuracy of active surveillance. PSMA PET scan is a test to find where prostate cancer is located. Patients have an injection of a chemical that attaches to prostate cancer and glows on a scan. Doctors can see areas where prostate cancer is on a PSMA PET scan. A key question on this trial is whether including PSMA PET will improve the accuracy of finding more aggressive prostate cancer in patients on active surveillance. In this study, all men will receive standard active surveillance tests, including PSA, biopsy, and MRI. In addition, participants will undergo PSMA PET before biopsy. Doctors will continue to monitor all participants over time for any symptoms or signs that the cancer is growing. The primary benefit of enrolling on this trial is helping future patients on active surveillance receive more accurate information about their cancer.